Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE009 (AUS) (Dr. Novak)
· consented 2022-09-18
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-09 (study day 45); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-18 (study day 146); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-04-13 (study day 200); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Fatigue — outcome: UNKNOWN; onset 2024-03-18 (study day 540); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-03-30 (study day 552); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.